India highlights new drug-ingredient plants under manufacturing incentives
A government update describes domestic capacity for antibiotic inputs and other essential pharmaceutical ingredients.
India’s Department of Pharmaceuticals has published an update on five greenfield projects supported by the production-linked incentive scheme for bulk drugs. The 25 September release describes manufacturing facilities for ingredients used in antibiotics, cardiovascular medicines and paracetamol.
Among them is a Penicillin G facility in Andhra Pradesh with stated capacity of 15,000 tonnes a year. The department also identifies a potassium clavulanate plant in Himachal Pradesh and facilities for other pharmaceutical inputs in Andhra Pradesh, Gujarat and Punjab.
The government presents these projects as a way to reduce exposure to imported starting materials and strengthen domestic supply chains. The release reports investment, employment and cumulative-production figures, which are claims from the department rather than independently audited findings by this publication.
Installed capacity, actual output and access to affordable finished medicines are different measures. This update provides evidence of the government’s manufacturing programme and its reported facilities; it does not by itself show that retail medicine prices have fallen or that all supply vulnerabilities have been resolved.